Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089101 · ClinicalTrials.gov registry record · Phase 1
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
A Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 17
- Study locations
NCT01089101 is a Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 217 participants, above the 104-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (109% higher). The trial reports 17 study locations across 12 states.
The verdict
NCT01089101, a Phase 1 study of Low Grade Glioma and Recurrent Visual Pathway Glioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 17
- Study locations
Study Summary
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Selumetinib
Study Locations (17)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mount Zion - San Francisco
- UCSF Medical Center-Parnassus - San Francisco
Illinois
- Lurie Children's Hospital-Chicago - Chicago
- Children's Memorial Outpatient Center in Lincoln Park - Chicago
Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- Texas Children's Hospital - Houston
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Maryland
- National Institutes of Health Clinical Center - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-07-07 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089101
The ClinicalTrials.gov registry entry for NCT01089101 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 104-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (109% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT01089101 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT01089101 about?
NCT01089101 is a clinical study titled "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma". This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocki...
What is the current status of trial NCT01089101?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2010-07-07. Estimated completion is 2027-03-18.
What conditions does trial NCT01089101 study?
This clinical trial studies the following conditions: Low Grade Glioma, Recurrent Visual Pathway Glioma, Refractory Visual Pathway Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1.
What interventions are being tested in trial NCT01089101?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT01089101?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01089101 being conducted?
This trial has 17 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
-
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
RECRUITING · Phase 1
-
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.